Clinical Trials

50 enrolled

GastrointestinalGynecologic

Esophageal Neoplasms, Gastrointestinal Neoplasms

NCT01719926 2026-06-04

PIFA

Phase 1 Completed

13 enrolled

Esophageal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03132922 2026-06-04

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Phase 1 Active not recruiting

71 enrolled 20 charts

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04458259 2026-06-04

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1 Terminated

88 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT06760819 2026-06-04

panSOHO

BreastGastrointestinalGenitourinaryGynecologicSarcoma

111 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07213791 2026-06-04

FiREBOLT

BreastGastrointestinalGynecologic

241 enrolled

Pancreatic Intraductal Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07625930 2026-06-04

RESTAGE

Phase 2 Not yet recruiting

184 enrolled

Phase 2 Active not recruiting

Esophageal Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT07114601 2026-06-03

OMNIRAY

BreastGastrointestinalGenitourinaryGynecologic

421 enrolled

Breast Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3 Completed

203 enrolled 22 charts

Phase 3 Active not recruiting

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT04513418 2026-06-02

POINT

244 enrolled

Phase 3 Not yet recruiting

Esophageal Neoplasms

NCT06914011 2026-06-02

MRD2START

172 enrolled

Esophageal Neoplasms

NCT07217704 2026-06-02

FAPI-GO

Phase 3 Recruiting

200 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT05704530 2026-06-01

Liquid Biopsies in Esophageal Cancer

248 enrolled

Esophageal Neoplasms

NCT06995898 2026-06-01

The Vanguard Study: Testing a New Way to Screen for Cancer

BreastGastrointestinalGenitourinaryGynecologicThoracic

24,000 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07617246 2026-06-01

The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer

Phase 2 Active not recruiting

120 enrolled

GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms

NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

94 enrolled 8 charts

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07162506 2026-05-29

DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

120 enrolled

Phase 2 Not yet recruiting

Esophageal Neoplasms

NCT07603375 2026-05-29

TNT Esophagus

60 enrolled

Phase 1/2 Active not recruiting

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT05094336 2026-05-28

MTAPESTRY 101

329 enrolled

CNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioma, Stomach Neoplasms

NCT06010303 2026-05-28

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Completed

118 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06123338 2026-05-28

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

49 enrolled

Esophageal Neoplasms

NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

2,130 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Phase 1/2 Recruiting

230 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Phase 1/2 Recruiting

160 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06872515 2026-05-26

Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)

20 enrolled

Phase 2 Active not recruiting

Esophageal Neoplasms, Motor Activity

NCT04494009 2026-05-22

RHAPSODY

110 enrolled

Esophageal Neoplasms

NCT06067438 2026-05-22

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

90 enrolled

Phase 1 Active not recruiting

Atrial Fibrillation, Esophageal Neoplasms

NCT06238479 2026-05-22

EXCEED

490 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06263088 2026-05-22

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

EndocrineGastrointestinalNET

200 enrolled

Anus Neoplasms, Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Neuroendocrine Tumors

NCT06437288 2026-05-22

Hematoporphyrin Photodynamic Therapy for Esophageal Cancer

Phase 4 Enrolling by invitation

198 enrolled

Esophageal Neoplasms

NCT06465069 2026-05-22

NEXUS-01

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

420 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT07578571 2026-05-22

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

BreastGastrointestinalThoracic

175 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07038629 2026-05-20

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

52 enrolled

Esophageal Neoplasms

NCT04846309 2026-05-19

PIONEER

16 enrolled

Phase 3 Active not recruiting

Esophageal Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT06414902 2026-05-19

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

60 enrolled

Esophageal Neoplasms

NCT07561840 2026-05-19

Exercise Training After Upper Gastrointestinal Cancer Surgery

171 enrolled

Phase 1/2 Not yet recruiting

Disease, Esophageal Neoplasms, Gastrointestinal Neoplasms, Motor Activity, Stomach Neoplasms

NCT07594626 2026-05-19

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

72 enrolled

Phase NA Not yet recruiting

Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms

NCT07596732 2026-05-19

SUNRISE

120 enrolled

GastrointestinalThoracic

Colonic Neoplasms, Disease, Esophageal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT04984733 2026-05-18

ELEVATE

Phase 2 Completed

13 enrolled

Esophageal Neoplasms, Neoplasms

NCT06769113 2026-05-18

A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

102 enrolled